♥

Kilitch Drugs (India) Limited

ISIN : INE729D01010
NSE : KILITCH
BSE : 524500
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 9.17
EPS (TTM) : 7.85
Price to Earning (P/E) : 39.54
Book Value : 109.40
Price to Bookvalue (P/B) : 3.31
Dividend Yield : 0 %
Return on Equity (ROE) : 8.43 %
Return on Capital Employed (ROCE) : 13.30 %

Kilitch Drugs share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	133.7 - 138.95 3.9 %
Low / High	132.25 - 139.5 5.5 %
Trade Volume	1,631
52 Week Low / High	121.1 - 500.05 312.9 %

YOU MAY ALSO LIKE

Share Market basics for beginners
Share Market jargons in simple terms
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
Stock market course tutorial
Stock Market Investment Course explained in simple words.
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR KILITCH DRUGS (INDIA) LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	366.08	334.53	306.97	299.72	454.77	365.57	412.02	317.94	448.19	334.52
Total Income	369.86	344.24	309.37	306.59	464.97	371.19	416.91	347.51	452.9	360.25
Total Expenditure	315.61	300.33	267.44	259.92	392.64	303.78	325.83	295.15	377.41	317.92
Other Income	3.78	9.71	2.4	6.87	10.2	5.62	4.89	29.56	4.71	25.74
Operating Profit	54.25	43.91	41.93	46.67	72.33	67.41	91.08	52.36	75.49	42.33
Interest	7.13	6.72	17.52	12.89	12.07	14.99	15.09	15.99	13.22	17.32
PBDT	47.12	37.19	24.41	33.78	60.26	52.42	75.99	36.37	62.27	25.01
Depreciation	11.27	8.23	8.87	9.27	9.14	7.89	8.17	8.15	9.29	8.51
Profit Before Tax	35.85	28.96	15.54	24.51	51.12	44.53	67.82	28.22	52.98	16.5
Tax	12.85	11.6	-3.83	7.43	22.1	13.93	16.89	10.8	16.16	15.38
Profit After Tax	23	17.36	19.37	17.08	29.02	30.6	50.93	17.42	36.82	1.12
Net Profit	23	17.36	19.37	17.08	29.02	30.6	50.93	17.42	36.82	1.12
Equity Capital	155.82	155.82	155.82	155.82	155.82	155.82	160.82	160.82	160.82	160.82
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Reserves					1360.15
Calculated EPS	1.86	1.34	1.56	1.52	2.29	2.15	2.95	1.81	2.23	0.83
Diluted Eps After Extraordinary Items	1.86	1.34	1.56	1.52	2.29	2.15	2.93	1.85	2.24	0.83
Diluted Eps Before Extraordinary Items	1.86	1.34	1.56	1.52	2.29	2.15	2.93	1.85	2.24	0.83

STANDALONE QUARTERLY RESULT FOR KILITCH DRUGS (INDIA) LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	320.31	235.69	224.28	285.03	432.83	311.25	315.74	297.65	391.36	334.22
Total Income	327.99	249.61	230.89	296.16	447.15	321.03	324.93	331.6	400.32	366.33
Total Expenditure	280.54	204.42	192.85	242.88	365.96	258.86	258.56	257.47	339.19	302.02
Other Income	7.68	13.92	6.61	11.13	14.32	9.78	9.19	33.95	8.96	32.12
Operating Profit	47.45	45.19	38.04	53.28	81.19	62.17	66.37	74.13	61.13	64.31
Interest	1.77	0.73	2.28	2.77	4.07	3.79	4.25	5.35	4.45	4.9
PBDT	45.68	44.46	35.76	50.51	77.12	58.38	62.12	68.78	56.68	59.41
Depreciation	2.59	2.72	3.13	3.78	3.73	2.57	2.79	2.99	4.1	3.49
Profit Before Tax	43.09	41.74	32.63	46.73	73.39	55.81	59.33	65.79	52.58	55.92
Tax	12.85	11.6	-3.83	7.44	22.11	13.93	16.9	10.81	16.16	15.38
Profit After Tax	30.24	30.14	36.46	39.29	51.28	41.88	42.43	54.98	36.42	40.54
Net Profit	30.24	30.14	36.46	39.29	51.28	41.88	42.43	54.98	36.42	40.54
Equity Capital	155.82	155.82	155.82	155.82	155.82	155.82	160.82	160.82	160.82	160.82
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	1.94	1.93	2.34	2.52	3.29	2.69	2.64	3.42	2.26	2.52
Diluted Eps After Extraordinary Items	1.94	1.93	2.34	2.53	3.29	2.69	2.6	3.48	2.26	2.52
Diluted Eps Before Extraordinary Items	1.94	1.93	2.34	2.53	3.29	2.69	2.6	3.48	2.26	2.52

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR KILITCH DRUGS (INDIA) LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	1142.34	1395.99	1543.72
Total Income	1171.44	1425.17	1588.51
Total Expenditure	1038.64	1220.34	1302.17
Other Income	29.09	29.18	44.79
Operating Profit	132.8	204.83	286.34
Interest	11.98	49.19	59.29
PBDT	120.82	155.64	227.05
Depreciation	24.66	35.51	33.5
Profit Before Tax	96.16	120.13	193.55
Tax	34.01	37.31	57.79
Profit After Tax	62.15	82.82	135.76
Net Profit	62.15	82.82	135.76
Equity Capital	155.82	155.82	160.82
Face Value (IN RS)	10	10	10
Reserves	1235.04	1360.15	1602.09
Calculated EPS	4.73	6.71	9.08
Diluted Eps After Extraordinary Items	4.73	6.71	9.17
Diluted Eps Before Extraordinary Items	4.73	6.71	9.17

STANDALONE ANNUAL RESULT FOR KILITCH DRUGS (INDIA) LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	1051.6	1177.84	1315.99
Total Income	1097.19	1223.81	1377.88
Total Expenditure	941.64	1006.1	1112.82
Other Income	45.59	45.98	61.89
Operating Profit	155.55	217.71	265.06
Interest	6.63	9.85	19.08
PBDT	148.92	207.86	245.98
Depreciation	9.64	13.37	12.44
Profit Before Tax	139.28	194.49	233.54
Tax	34.01	37.31	57.79
Profit After Tax	105.27	157.18	175.75
Net Profit	105.27	157.18	175.75
Equity Capital	155.82	155.82	160.82
Face Value (IN RS)	10	10	10
Reserves	1624.49	1803.49	2068.41
Calculated EPS	6.76	10.09	10.93
Diluted Eps After Extraordinary Items	6.76	10.09	11.03
Diluted Eps Before Extraordinary Items	6.76	10.09	11.03

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	68.68 Cr	114.23 Cr	139.6 Cr	154.37 Cr
Sales	68.29 Cr	112.96 Cr	138.86 Cr	153.61 Cr
Net Sales	68.52 Cr	114.23 Cr	139.6 Cr	154.37 Cr
Increase/Decrease in Stock	1.09 Cr	-4.69 Lk	22.67 Lk	-11.61 Lk
Raw Material Consumed	36.22 Cr	65.48 Cr	74.53 Cr	79.08 Cr
Opening Raw Materials	3.67 Cr	2.79 Cr	4.16 Cr	1.43 Cr
Purchases Raw Materials	35.34 Cr	66.85 Cr	71.8 Cr	80.91 Cr
Closing Raw Materials	2.79 Cr	4.16 Cr	1.43 Cr	3.25 Cr
Power & Fuel Cost	1.63 Cr	2 Cr	2.15 Cr	2.43 Cr
Electricity & Power	1.57 Cr	1.92 Cr	2.06 Cr	2.32 Cr
Employee Cost	5.24 Cr	6.18 Cr	11.73 Cr	10.01 Cr
Salaries, Wages & Bonus	4.96 Cr	5.71 Cr	11.27 Cr	9.29 Cr
Contributions to EPF & Pension Funds	18.74 Lk	23.45 Lk	25.55 Lk	26.78 Lk
Workmen and Staff Welfare Expenses	20.59 Lk	20.36 Lk	21 Lk	45.98 Lk
Other Manufacturing Expenses	3.65 Cr	5.91 Cr	5.37 Cr	4.76 Cr
Processing Charges	2.23 Cr	2.29 Cr	2.33 Cr	2.82 Cr
Repairs and Maintenance	60.54 Lk	1.5 Cr	65.71 Lk	43.03 Lk
General and Administration Expenses	5.71 Cr	5.9 Cr	8.73 Cr	8.21 Cr
Rent , Rates & Taxes	32.49 Lk	48.79 Lk	37.73 Lk	1.39 Cr
Insurance	3.33 Lk	13.02 Lk	20.28 Lk	30.78 Lk
Printing and stationery	8.52 Lk	11.04 Lk	10.02 Lk	20.79 Lk
Professional and legal fees	3.98 Cr	3.33 Cr	6.32 Cr	3.24 Cr
Traveling and conveyance	77.62 Lk	1.12 Cr	1.37 Cr	2.13 Cr
Selling and Distribution Expenses	7.22 Cr	10.73 Cr	14.81 Cr	20.04 Cr
Advertisement & Sales Promotion	68.28 Lk	61.66 Lk	65.95 Lk	1.11 Cr
Sales Commissions & Incentives	2.01 Cr	2.97 Cr	6.47 Cr	13.91 Cr
Freight and Forwarding	4.09 Cr	6.97 Cr	7.49 Cr	4.97 Cr
Miscellaneous Expenses	2.44 Cr	7.58 Cr	4.32 Cr	5.7 Cr
Bad debts /advances written off	33.73 Lk	17.06 Lk	0	0
Provision for doubtful debts	0	91.51 Lk	2.97 Cr	2.36 Cr
Loss on foreign exchange fluctuations	7.25 Lk	71.76 Lk	0	16.93 Lk
Loss on sale of non-trade current investments	20,000	20,000	19,000	20,000
Total Expenditure	63.21 Cr	103.73 Cr	121.87 Cr	130.11 Cr
Other Income	2.67 Cr	2.91 Cr	2.92 Cr	4.48 Cr
Interest Received	17.03 Lk	21.91 Lk	30.17 Lk	40.79 Lk
Dividend Received	5.55 Lk	3.05 Lk	87,000	1.2 Lk
Profits on sale of Investments	1.2 Cr	1.36 Cr	98.8 Lk	1.39 Cr
Provision Written Back	1.03 Lk	0	0	0
Foreign Exchange Gains	1.05 Cr	1.04 Cr	1.56 Cr	2.17 Cr
Operating Profit	7.98 Cr	13.41 Cr	20.65 Cr	28.74 Cr
Interest	87.69 Lk	1.33 Cr	5.08 Cr	6.04 Cr
Bank Charges etc	12.25 Lk	13.26 Lk	16.4 Lk	10.7 Lk
PBDT	7.11 Cr	12.08 Cr	15.56 Cr	22.7 Cr
Depreciation	1.99 Cr	2.47 Cr	3.55 Cr	3.35 Cr
Profit Before Taxation & Exceptional Items	5.12 Cr	9.61 Cr	12.01 Cr	19.35 Cr
Profit Before Tax	5.12 Cr	9.61 Cr	12.01 Cr	19.35 Cr
Provision for Tax	1.35 Cr	3.4 Cr	3.73 Cr	5.78 Cr
Current Income Tax	1.67 Cr	3.63 Cr	4.2 Cr	6.36 Cr
Deferred Tax	-31.25 Lk	-23.3 Lk	-46.6 Lk	-58.57 Lk
Profit After Tax	3.77 Cr	6.21 Cr	8.28 Cr	13.58 Cr
Minority Interest	-9.55 Lk	1.15 Cr	2.17 Cr	1.03 Cr
Consolidated Net Profit	3.67 Cr	7.37 Cr	10.45 Cr	14.6 Cr
Profit Balance B/F	48.14 Cr	51.82 Cr	59.18 Cr	69.63 Cr
Appropriations	51.82 Cr	59.18 Cr	69.63 Cr	84.23 Cr
Earnings Per Share	2.37	4.73	6.71	9.08
Adjusted EPS	2.37	4.73	6.71	9.08

STANDALONE PROFIT / LOSS FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	70.18 Cr	105.16 Cr	117.78 Cr	131.6 Cr
Sales	69.78 Cr	103.88 Cr	117.04 Cr	130.83 Cr
Net Sales	70.02 Cr	105.16 Cr	117.78 Cr	131.6 Cr
Increase/Decrease in Stock	1.09 Cr	-4.69 Lk	22.68 Lk	-11.61 Lk
Raw Material Consumed	37.97 Cr	60.29 Cr	58.27 Cr	66.33 Cr
Opening Raw Materials	3.67 Cr	2.79 Cr	4.16 Cr	1.43 Cr
Purchases Raw Materials	37.09 Cr	61.65 Cr	55.54 Cr	68.16 Cr
Closing Raw Materials	2.79 Cr	4.16 Cr	1.43 Cr	3.25 Cr
Power & Fuel Cost	1.63 Cr	2 Cr	2.15 Cr	2.36 Cr
Electricity & Power	1.57 Cr	1.92 Cr	2.06 Cr	2.25 Cr
Employee Cost	5.22 Cr	6.15 Cr	7.47 Cr	7.91 Cr
Salaries, Wages & Bonus	4.93 Cr	5.68 Cr	7 Cr	7.41 Cr
Contributions to EPF & Pension Funds	18.74 Lk	23.45 Lk	25.55 Lk	26.78 Lk
Workmen and Staff Welfare Expenses	20.58 Lk	20.36 Lk	21 Lk	23.38 Lk
Other Manufacturing Expenses	3.65 Cr	5.91 Cr	5.37 Cr	4.77 Cr
Processing Charges	2.23 Cr	2.29 Cr	2.33 Cr	2.82 Cr
Repairs and Maintenance	60.54 Lk	1.5 Cr	65.71 Lk	36.22 Lk
General and Administration Expenses	5.69 Cr	5.88 Cr	9.16 Cr	6.81 Cr
Rent , Rates & Taxes	31.39 Lk	48.76 Lk	37.73 Lk	47.02 Lk
Insurance	3.33 Lk	13.02 Lk	20.28 Lk	15.44 Lk
Printing and stationery	8.52 Lk	10.77 Lk	10.02 Lk	20.79 Lk
Professional and legal fees	3.98 Cr	3.32 Cr	6.32 Cr	3.24 Cr
Traveling and conveyance	77.61 Lk	1.12 Cr	1.37 Cr	2.09 Cr
Selling and Distribution Expenses	7.2 Cr	10.67 Cr	13.92 Cr	19.81 Cr
Advertisement & Sales Promotion	68.28 Lk	61.66 Lk	65.95 Lk	92.53 Lk
Sales Commissions & Incentives	2.01 Cr	2.92 Cr	6.35 Cr	13.89 Cr
Freight and Forwarding	4.06 Cr	6.97 Cr	6.72 Cr	4.96 Cr
Miscellaneous Expenses	2.23 Cr	3.17 Cr	3.88 Cr	3.29 Cr
Bad debts /advances written off	33.73 Lk	14.95 Lk	0	0
Provision for doubtful debts	0	91.51 Lk	2.97 Cr	2.36 Cr
Loss on foreign exchange fluctuations	1.25 Lk	71.76 Lk	0	0
Loss on sale of non-trade current investments	20,000	20,000	19,000	20,000
Total Expenditure	64.69 Cr	94.03 Cr	100.45 Cr	111.18 Cr
Other Income	4.19 Cr	4.56 Cr	4.6 Cr	6.19 Cr
Interest Received	1.77 Cr	1.96 Cr	1.99 Cr	2.12 Cr
Dividend Received	5.55 Lk	3.05 Lk	87,000	1.2 Lk
Profits on sale of Investments	1.2 Cr	1.36 Cr	98.8 Lk	1.39 Cr
Provision Written Back	1.03 Lk	0	0	0
Foreign Exchange Gains	98.67 Lk	1.04 Cr	1.56 Cr	2.17 Cr
Operating Profit	9.53 Cr	15.69 Cr	21.93 Cr	26.61 Cr
Interest	87.58 Lk	79.51 Lk	1.15 Cr	2.02 Cr
Bank Charges etc	12.14 Lk	13.24 Lk	16.38 Lk	10.69 Lk
PBDT	8.65 Cr	14.89 Cr	20.79 Cr	24.6 Cr
Depreciation	1.14 Cr	96.42 Lk	1.34 Cr	1.24 Cr
Profit Before Taxation & Exceptional Items	7.51 Cr	13.93 Cr	19.45 Cr	23.35 Cr
Profit Before Tax	7.51 Cr	13.93 Cr	19.45 Cr	23.35 Cr
Provision for Tax	1.35 Cr	3.4 Cr	3.73 Cr	5.78 Cr
Current Income Tax	1.67 Cr	3.63 Cr	4.2 Cr	6.36 Cr
Deferred Tax	-31.26 Lk	-23.32 Lk	-46.63 Lk	-58.57 Lk
Profit After Tax	6.16 Cr	10.53 Cr	15.72 Cr	17.57 Cr
Consolidated Net Profit	6.16 Cr	10.53 Cr	15.72 Cr	17.57 Cr
Profit Balance B/F	81.56 Cr	87.71 Cr	98.24 Cr	120.29 Cr
Appropriations	87.71 Cr	98.24 Cr	113.96 Cr	137.86 Cr
Other Appropriation	0	0	-6.33 Cr	-5.56 Cr
Earnings Per Share	3.97	6.76	10.09	10.93
Adjusted EPS	3.97	6.76	10.09	10.93

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR KILITCH DRUGS (INDIA) LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	5.12 Cr	9.61 Cr	12.01 Cr	19.35 Cr
Adjustment	2.8 Cr	3.89 Cr	9.79 Cr	11.85 Cr
Changes In working Capital	38.75 Cr	-5.19 Cr	-14.88 Cr	-24.31 Cr
Cash Flow after changes in Working Capital	46.67 Cr	8.32 Cr	6.92 Cr	6.89 Cr
Cash Flow from Operating Activities	45.66 Cr	5.78 Cr	2.59 Cr	-14.63 Lk
Cash Flow from Investing Activities	-37.57 Cr	-15.25 Cr	7.92 Cr	-9.54 Cr
Cash Flow from Financing Activitie	1.61 Cr	7.03 Cr	-71.63 Lk	8.81 Cr
Net Cash Inflow / Outflow	9.7 Cr	-2.44 Cr	9.78 Cr	-88.42 Lk
Opening Cash & Cash Equivalents	2.8 Cr	12.5 Cr	10.06 Cr	19.85 Cr
Closing Cash & Cash Equivalent	12.5 Cr	10.06 Cr	19.85 Cr	18.96 Cr

STANDALONE CASH FLOW FOR KILITCH DRUGS (INDIA) LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	7.51 Cr	13.93 Cr	19.45 Cr	23.35 Cr
Adjustment	-46.15 Lk	9.59 Lk	1.95 Cr	3.25 Cr
Changes In working Capital	9.12 Lk	-6.28 Cr	-10.97 Cr	-20.76 Cr
Cash Flow after changes in Working Capital	7.14 Cr	7.74 Cr	10.43 Cr	5.84 Cr
Cash Flow from Operating Activities	6.13 Cr	5.2 Cr	6.1 Cr	-1.19 Cr
Cash Flow from Investing Activities	-5.35 Cr	-16.08 Cr	6.24 Cr	-10.1 Cr
Cash Flow from Financing Activitie	2.27 Cr	7.55 Cr	3.04 Cr	11.4 Cr
Net Cash Inflow / Outflow	3.05 Cr	-3.32 Cr	15.39 Cr	11.3 Lk
Opening Cash & Cash Equivalents	2.72 Cr	5.77 Cr	2.45 Cr	17.84 Cr
Closing Cash & Cash Equivalent	5.77 Cr	2.45 Cr	17.84 Cr	17.95 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Equity - Authorised	20 Cr	20 Cr	25 Cr	25 Cr
Equity - Issued	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Equity Paid Up	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Face Value	10	10	10	10
Total Reserves	111.28 Cr	120.65 Cr	130.66 Cr	159.86 Cr
Securities Premium	38.33 Cr	38.33 Cr	38.33 Cr	46.68 Cr
Capital Reserves	71.28 Lk	71.28 Lk	71.28 Lk	71.28 Lk
Profit & Loss Account Balance	51.82 Cr	59.18 Cr	69.63 Cr	84.23 Cr
General Reserves	15.8 Cr	15.8 Cr	15.8 Cr	15.8 Cr
Reserve excluding Revaluation Reserve	111.28 Cr	120.65 Cr	130.66 Cr	159.86 Cr
Shareholder's Funds	127.13 Cr	139.09 Cr	151.6 Cr	176.29 Cr
Minority Interest	2.35 Cr	1.21 Cr	-1.02 Cr	-61.79 Lk
Deferred Tax Assets / Liabilities	-1.28 Cr	-1.51 Cr	-1.98 Cr	-2.56 Cr
Deferred Tax Assets	1.28 Cr	1.51 Cr	1.98 Cr	2.56 Cr
Long Term Provisions	38.06 Lk	27.54 Lk	6.83 Lk	17.24 Lk
Total Non-Current Liabilities	-89.81 Lk	-1.24 Cr	-1.91 Cr	-2.39 Cr
Trade Payables	53.65 Cr	42.87 Cr	40.87 Cr	25.59 Cr
Sundry Creditors	53.65 Cr	42.87 Cr	40.87 Cr	25.59 Cr
Other Current Liabilities	1.41 Cr	57.33 Lk	24.99 Lk	28.42 Lk
Short Term Borrowings	14.8 Cr	20.43 Cr	22.19 Cr	31.65 Cr
Secured ST Loans repayable on Demands	14.71 Cr	20.33 Cr	21.86 Cr	31.32 Cr
Working Capital Loans- Sec	14.71 Cr	17.95 Cr	20.41 Cr	30.87 Cr
Short Term Provisions	3.45 Cr	5.4 Cr	5.56 Cr	6.7 Cr
Provision for Tax	2.62 Cr	4.4 Cr	4.04 Cr	5.31 Cr
Provision for post retirement benefits	45.86 Lk	48.08 Lk	1.38 Cr	1.25 Cr
Total Current Liabilities	73.32 Cr	69.28 Cr	68.87 Cr	64.22 Cr
Total Liabilities	201.9 Cr	208.34 Cr	217.54 Cr	237.5 Cr
Gross Block	71.01 Cr	108.05 Cr	111.28 Cr	112.39 Cr
Less: Accumulated Depreciation	41.05 Cr	43.51 Cr	47.06 Cr	50.41 Cr
Net Block	29.96 Cr	64.54 Cr	64.22 Cr	61.98 Cr
Capital Work in Progress	65.48 Cr	3.16 Cr	3.62 Cr	5.96 Cr
Non Current Investments	23.88 Cr	23.93 Cr	22.66 Cr	22.83 Cr
Long Term Investment	23.88 Cr	23.93 Cr	22.66 Cr	22.83 Cr
Quoted	98.73 Lk	1.01 Cr	94.23 Lk	1.08 Cr
Unquoted	22.9 Cr	22.92 Cr	21.72 Cr	21.76 Cr
Long Term Loans & Advances	44.14 Lk	46.31 Lk	62.06 Lk	71.51 Lk
Other Non Current Assets	1.76 Cr	2.14 Cr	1.79 Lk	1.25 Lk
Total Non-Current Assets	121.53 Cr	94.23 Cr	91.14 Cr	91.51 Cr
Currents Investments	36.4 Cr	47.23 Cr	39.2 Cr	49.43 Cr
Quoted	36.4 Cr	47.23 Cr	39.2 Cr	49.43 Cr
Unquoted	22.9 Cr	22.92 Cr	21.72 Cr	21.76 Cr
Inventories	3.59 Cr	5 Cr	2.04 Cr	3.99 Cr
Raw Materials	2.79 Cr	4.16 Cr	1.43 Cr	3.25 Cr
Work-in Progress	34.56 Lk	39.86 Lk	16.75 Lk	18.68 Lk
Finished Goods	45.17 Lk	44.55 Lk	44.99 Lk	54.67 Lk
Sundry Debtors	22.92 Cr	41.41 Cr	54.29 Cr	63.22 Cr
Debtors more than Six months	22.92 Cr	21.06 Cr	14.67 Cr	14.42 Cr
Debtors Others	3.32 Cr	24.59 Cr	46.39 Cr	57.93 Cr
Cash and Bank	12.5 Cr	10.06 Cr	19.98 Cr	19.64 Cr
Cash in hand	84,000	90,000	1.31 Lk	1.32 Lk
Balances at Bank	12.49 Cr	10.05 Cr	19.97 Cr	19.63 Cr
Other Current Assets	4.58 Lk	35.78 Lk	54.2 Lk	1.71 Cr
Interest accrued and or due on loans	1.97 Lk	2.02 Lk	2.15 Lk	3.37 Lk
Prepaid Expenses	2.61 Lk	4.97 Lk	15.81 Lk	8.59 Lk
Short Term Loans and Advances	4.91 Cr	10.04 Cr	10.35 Cr	8 Cr
Advances recoverable in cash or in kind	1.8 Cr	8.37 Cr	8 Cr	5.33 Cr
Total Current Assets	80.36 Cr	114.1 Cr	126.4 Cr	145.99 Cr
Net Current Assets (Including Current Investments)	7.05 Cr	44.83 Cr	57.53 Cr	81.78 Cr
Total Assets	201.9 Cr	208.34 Cr	217.54 Cr	237.5 Cr
Contingent Liabilities	5.8 Cr	76.05 Lk	76.05 Lk	0
Total Debt	14.8 Cr	20.43 Cr	22.19 Cr	31.65 Cr
Book Value	81.82	87.43	0	109.4
Adjusted Book Value	81.82	87.43	93.85	109.4

STANDALONE BALANCE SHEET FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Equity - Authorised	20 Cr	20 Cr	25 Cr	25 Cr
Equity - Issued	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Equity Paid Up	15.49 Cr	15.58 Cr	15.58 Cr	16.08 Cr
Face Value	10	10	10	10
Total Reserves	147.08 Cr	159.6 Cr	174.99 Cr	206.49 Cr
Securities Premium	38.33 Cr	38.33 Cr	38.33 Cr	46.68 Cr
Capital Reserves	58 Lk	58 Lk	58 Lk	58 Lk
Profit & Loss Account Balance	87.71 Cr	98.24 Cr	120.29 Cr	143.43 Cr
General Reserves	15.8 Cr	15.8 Cr	15.8 Cr	15.8 Cr
Reserve excluding Revaluation Reserve	147.08 Cr	159.6 Cr	174.99 Cr	206.49 Cr
Shareholder's Funds	162.93 Cr	178.03 Cr	195.93 Cr	222.92 Cr
Deferred Tax Assets / Liabilities	-1.27 Cr	-1.51 Cr	-1.97 Cr	-2.56 Cr
Deferred Tax Assets	1.27 Cr	1.51 Cr	1.97 Cr	2.56 Cr
Long Term Provisions	38.06 Lk	27.54 Lk	6.83 Lk	17.24 Lk
Total Non-Current Liabilities	-89.38 Lk	-1.23 Cr	-1.91 Cr	-2.39 Cr
Trade Payables	13.56 Cr	27.77 Cr	28.84 Cr	26.16 Cr
Sundry Creditors	13.56 Cr	27.77 Cr	28.84 Cr	26.16 Cr
Other Current Liabilities	83.97 Lk	47.78 Lk	16.65 Lk	28.42 Lk
Short Term Borrowings	14.71 Cr	20.33 Cr	21.86 Cr	31.32 Cr
Secured ST Loans repayable on Demands	14.71 Cr	20.33 Cr	21.86 Cr	31.32 Cr
Working Capital Loans- Sec	14.71 Cr	20.33 Cr	21.86 Cr	31.32 Cr
Short Term Provisions	3.43 Cr	5.4 Cr	5.55 Cr	6.61 Cr
Provision for Tax	2.62 Cr	4.4 Cr	4.04 Cr	5.31 Cr
Provision for post retirement benefits	44.06 Lk	48.08 Lk	1.38 Cr	1.21 Cr
Total Current Liabilities	32.53 Cr	53.99 Cr	56.42 Cr	64.37 Cr
Total Liabilities	194.57 Cr	230.78 Cr	250.44 Cr	284.91 Cr
Gross Block	27.73 Cr	35.93 Cr	38.16 Cr	40.03 Cr
Less: Accumulated Depreciation	20.78 Cr	21.75 Cr	23.08 Cr	24.33 Cr
Net Block	6.94 Cr	14.18 Cr	15.08 Cr	15.7 Cr
Capital Work in Progress	0	0	1.31 Cr	5.96 Cr
Non Current Investments	70.1 Cr	70.15 Cr	71.1 Cr	71.27 Cr
Long Term Investment	70.1 Cr	70.15 Cr	71.1 Cr	71.27 Cr
Quoted	98.73 Lk	1.01 Cr	94.22 Lk	1.08 Cr
Unquoted	69.11 Cr	69.14 Cr	70.16 Cr	70.2 Cr
Long Term Loans & Advances	44 Cr	46.6 Cr	48.17 Cr	50.47 Cr
Other Non Current Assets	1.76 Cr	2.14 Cr	1.79 Lk	1.25 Lk
Total Non-Current Assets	122.81 Cr	133.06 Cr	135.68 Cr	143.42 Cr
Currents Investments	36.4 Cr	47.23 Cr	39.2 Cr	49.43 Cr
Quoted	36.4 Cr	47.23 Cr	39.2 Cr	49.43 Cr
Unquoted	69.11 Cr	69.14 Cr	70.16 Cr	70.2 Cr
Inventories	3.59 Cr	5 Cr	2.04 Cr	3.99 Cr
Raw Materials	2.79 Cr	4.16 Cr	1.43 Cr	3.25 Cr
Work-in Progress	34.56 Lk	39.86 Lk	16.75 Lk	18.68 Lk
Finished Goods	45.17 Lk	44.56 Lk	44.99 Lk	54.67 Lk
Sundry Debtors	22.92 Cr	41.42 Cr	53.1 Cr	61.8 Cr
Debtors more than Six months	22.92 Cr	20.72 Cr	13.51 Cr	18.26 Cr
Debtors Others	3.32 Cr	24.94 Cr	46.36 Cr	52.67 Cr
Cash and Bank	5.77 Cr	2.45 Cr	17.97 Cr	18.63 Cr
Cash in hand	71,000	45,000	1.02 Lk	1.11 Lk
Balances at Bank	5.77 Cr	2.45 Cr	17.96 Cr	18.62 Cr
Other Current Assets	4.58 Lk	6.99 Lk	17.7 Lk	11.96 Lk
Interest accrued and or due on loans	1.97 Lk	2.02 Lk	2.15 Lk	3.37 Lk
Prepaid Expenses	2.61 Lk	4.97 Lk	15.55 Lk	8.59 Lk
Short Term Loans and Advances	3.04 Cr	1.54 Cr	2.28 Cr	7.52 Cr
Advances recoverable in cash or in kind	2.78 Lk	44,000	27,000	4.99 Cr
Total Current Assets	71.76 Cr	97.72 Cr	114.77 Cr	141.49 Cr
Net Current Assets (Including Current Investments)	39.23 Cr	43.73 Cr	58.35 Cr	77.11 Cr
Total Assets	194.57 Cr	230.78 Cr	250.44 Cr	284.91 Cr
Contingent Liabilities	5.8 Cr	76.05 Lk	76.05 Lk	0
Total Debt	14.71 Cr	20.33 Cr	21.86 Cr	31.32 Cr
Book Value	104.93	112.42	0	138.39
Adjusted Book Value	104.93	112.42	122.3	138.39

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	2.37	4.73	6.71	9.08
CEPS(Rs)	3.71	5.57	7.59	10.52
Book NAV/Share(Rs)	81.82	87.43	93.85	109.4
Tax Rate(%)	26.43	35.37	31.06	29.86
Margin Ratios
Core EBITDA Margin(%)	7.74	9.19	12.7	15.72
EBIT Margin(%)	8.73	9.58	12.25	16.45
Pre Tax Margin(%)	7.45	8.42	8.61	12.54
PAT Margin (%)	5.48	5.44	5.93	8.79
Cash Profit Margin (%)	8.38	7.6	8.48	10.96
Performance Ratios
ROA(%)	2.19	3.03	3.89	5.97
ROE(%)	3.09	4.73	5.86	8.43
ROCE(%)	4.4	7.26	10.26	13.3
Asset Turnover(x)	0.4	0.56	0.66	0.68
Sales/Fixed Asset(x)	0.97	1.28	1.27	1.38
Working Capital/Sales(x)	9.74	2.55	2.43	1.89
Efficiency Ratios
Fixed Capital/Sales(x)	1.03	0.78	0.79	0.72
Receivable days	103.04	102.77	125.11	138.92
Inventory Days	24.29	13.72	9.21	7.13
Payable days	197.67	269.21	204.43	153.61
Valuation Parameters
PER(x)	34.21	35.47	20.81	42.94
PCE(x)	21.83	30.11	18.38	37.04
Price/Book(x)	0.99	1.92	1.49	3.56
EV/Net Sales(x)	1.87	2.38	1.57	4.14
EV/Core EBITDA(x)	16.02	20.26	10.64	22.23
EV/EBIT(x)	21.33	24.82	12.85	25.17
EV/CE(x)	0.63	1.3	1.01	3.07
M Cap / Sales	1.83	2.29	1.56	4.06
Growth Ratio
Net Sales Growth(%)	28.51	66.71	22.2	10.58
Core EBITDA Growth(%)	75.65	68	53.96	39.19
EBIT Growth(%)	135.57	82.53	56.2	48.51
PAT Growth(%)	347.34	64.97	33.3	63.9
EPS Growth(%)	334.34	99.55	41.82	35.41
Financial Stability Ratios
Total Debt/Equity(x)	0.12	0.15	0.15	0.18
Current Ratio(x)	1.1	1.65	1.84	2.27
Quick Ratio(x)	1.05	1.57	1.81	2.21
Interest Cover(x)	6.84	8.22	3.36	4.21
Total Debt/Mcap(x)	0.12	0.08	0.1	0.05

FINANCIAL RATIOS (STANDALONE) FOR KILITCH DRUGS (INDIA) LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	3.97	6.76	10.09	10.93
CEPS(Rs)	4.71	7.37	10.94	11.7
Book NAV/Share(Rs)	104.93	112.42	122.3	138.39
Tax Rate(%)	18.02	24.41	19.19	24.75
Margin Ratios
Core EBITDA Margin(%)	7.6	10.58	14.72	15.52
EBIT Margin(%)	11.95	14	17.49	19.28
Pre Tax Margin(%)	10.7	13.24	16.51	17.75
PAT Margin (%)	8.77	10.01	13.34	13.35
Cash Profit Margin (%)	10.4	10.93	14.48	14.3
Performance Ratios
ROA(%)	3.35	4.95	6.53	6.57
ROE(%)	3.93	6.23	8.59	8.51
ROCE(%)	4.91	7.83	9.9	10.75
Asset Turnover(x)	0.38	0.49	0.49	0.49
Sales/Fixed Asset(x)	2.55	3.3	3.18	3.37
Working Capital/Sales(x)	1.79	2.4	2.02	1.71
Efficiency Ratios
Fixed Capital/Sales(x)	0.39	0.3	0.31	0.3
Receivable days	103.82	111.66	146.46	159.35
Inventory Days	23.78	14.9	10.92	8.37
Payable days	68.78	125.2	176.61	151.58
Valuation Parameters
PER(x)	20.4	24.82	13.84	35.68
PCE(x)	17.21	22.74	12.75	33.32
Price/Book(x)	0.77	1.49	1.14	2.82
EV/Net Sales(x)	1.92	2.66	1.88	4.86
EV/Core EBITDA(x)	14.12	17.8	10.09	24.04
EV/EBIT(x)	16.04	18.96	10.75	25.22
EV/CE(x)	0.69	1.21	0.88	2.52
M Cap / Sales	1.79	2.48	1.85	4.76
Growth Ratio
Net Sales Growth(%)	15.22	50.19	12	11.73
Core EBITDA Growth(%)	30.36	64.7	39.82	21.32
EBIT Growth(%)	36.24	75.61	39.9	23.16
PAT Growth(%)	38.1	71.03	49.29	11.81
EPS Growth(%)	37.56	70.07	49.29	8.34
Financial Stability Ratios
Total Debt/Equity(x)	0.09	0.12	0.11	0.14
Current Ratio(x)	2.21	1.81	2.03	2.2
Quick Ratio(x)	2.1	1.72	2	2.14
Interest Cover(x)	9.57	18.52	17.93	12.59
Total Debt/Mcap(x)	0.12	0.08	0.1	0.05

SHARE HOLDING PATTERN FOR KILITCH DRUGS (INDIA) LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	68.25	68.25	68.25	68.25	68.25	69.23	69.23	69.23	69.23	69.23
FII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Public %	31.75	31.75	31.75	31.75	31.75	30.77	30.77	30.77	30.77	30.76

PEER COMPARISON FOR KILITCH DRUGS (INDIA) LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR KILITCH DRUGS

Exchange Date	Purpose	Book Closure Dates
BSE 06-Sep-2024	AGM - A.G.M.	27-Sep-2024 27-Sep-2024
BSE 06-Sep-2024	Book Closure - A.G.M.	20-Sep-2024 27-Sep-2024
BSE 01-Aug-2024	Board Meeting - Quarterly Results	08-Aug-2024
BSE 21-May-2024	Board Meeting - Quarterly Results	27-May-2024
BSE 31-Jan-2024	Board Meeting - Quarterly Results	08-Feb-2024
BSE 01-Nov-2023	Board Meeting - Quarterly Results	09-Nov-2023
BSE 14-Aug-2023	Book Closure - A.G.M.	22-Sep-2023 29-Sep-2023
BSE 14-Aug-2023	AGM - A.G.M.	29-Sep-2023 29-Sep-2023
BSE 04-Aug-2023	Board Meeting - Quarterly Results	11-Aug-2023
BSE 19-Jul-2023	Board Meeting - Inter alia, to consider and approve conversion of warrants into the equity shares of the Company to the specified person only.	22-Jul-2023
BSE 17-May-2023	Board Meeting - Audited Results	29-May-2023
BSE 03-Feb-2023	Board Meeting - Quarterly Results	14-Feb-2023
BSE 03-Nov-2022	Board Meeting - Quarterly Results	14-Nov-2022
BSE 11-Aug-2022	Book Closure - A.G.M.	22-Sep-2022 29-Sep-2022
BSE 11-Aug-2022	AGM - A.G.M.	29-Sep-2022 29-Sep-2022
BSE 02-Aug-2022	Board Meeting - Quarterly Results	10-Aug-2022
BSE 17-May-2022	Board Meeting - Audited Results	26-May-2022
BSE 07-Feb-2022	Board Meeting - Quarterly Results	14-Feb-2022
BSE 15-Dec-2021	Board Meeting - Preferential Issue of shares & Issue Of Warrants	20-Dec-2021
BSE 02-Nov-2021	Board Meeting - Quarterly Results	12-Nov-2021

CORPORATE ANNOUNCEMENTS FOR KILITCH DRUGS

Exchange Date	Category File	Description
BSE 22-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation Of Loss of share certificate by Mr. Ved Bhushan received from Company to stock exchanges
BSE 19-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Issue of Duplicate Share Certificate under regulation 39(3) of the listing regulation to the stock exchange
BSE 09-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are submitting herewith the copy of certificate received from Registrar and Share Transfer Agent of the Company under Regulation 74(5) of SEBI (DP) Regulation 2018
BSE 07-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Duplicate Share Certificate to Mr. Vishwa Jit Sharma due to loss of original share certificate by him
BSE 27-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report We hereby submit Scrutinizer Report for the 32ND AGM of the Company
BSE 27-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM We hereby submit proceeding and outcome of 32nd Annual General meeting of the Company
BSE 25-Sep-2024	Intimation FILE	Closure of Trading Window We hereby inform you that the trading window for dealing in securities of the Company will remain closed for designated persons of the Company commencing from 1st October 2024 till expiry of 48 hours after the declaration of unaudited Financial Results of the Company for the quarter ended 30th September 2024
BSE 21-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Issue of Duplicate Share Certificates to shareholders to Stock Exchange under regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 13-Sep-2024	General Announcements FILE	Intimation To Stock Exchange Regarding Report Submitted By Acquirer To The SEBI Under Regulation 10(7) Of SEBI SAST Regulation intimation to stock exchange regarding report submitted by acquirer to the SEBI under regulation 10(7) of SEBI SAST regulation
BSE 03-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication We are submitting herewith the copy of extract of Notice of 32nd AGM published in the newspaper
BSE 02-Sep-2024	Intimation FILE	Intimation Of Book Closure We hereby inform you that the Register of Members and Register of Share Transfer shall remain closed from Friday 20th September 2024 till Friday 27th September 2024 for the purpose of AGM
BSE 02-Sep-2024	Intimation FILE	Notice Of 32Nd Annual General Meeting We are hereby submitting the Notice of 32nd Annual General Meeting of the Company to be held on 27th September 2024
BSE 02-Sep-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Pursuant to Regulations 34 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 we are submitting herewith the Annual Report for the Financial Year 2023-24
BSE 30-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s Pursuant to Regulation 30 of SEBI LODR Regulation this is to inform you that the Board of Directors at their meeting held today appointed M/s Sharat & Associates Chartered Accountant as Statutory Auditors of the Company
BSE 30-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Pursuant to Regulation 30 of SEBI LODR Regulations this is to inform you that the Board of Directors approved the appointment of M/s C Sharat & Company Chartered Accountants as a Statutory Auditors of the Company
BSE 30-Aug-2024	General FILE	Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mira Mehta
BSE 27-Aug-2024	General FILE	Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mira Bhavin Mehta
BSE 27-Aug-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mira Bhavin Mehta
BSE 26-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s Appointment of M/s. AVHP & Company LLP Chartered Accountant (FRN:W100671) as Statutory Auditors of the Company
BSE 20-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Duplicate Share certificate to S Mallikarjunappa
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors we hereby inform you that Suryaprakash Maurya co. Chartered Accountants statutory auditors of the Company have tendered their resignation vide letter dated 13th August 2024 informing their inability to continue as statutory auditor of the company with immediate effect.
BSE 13-Aug-2024	General FILE	Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mira Bhavin Mehta
BSE 10-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of Newspaper Publication of extract of financial results for the quarter ended 30th June 2024
BSE 08-Aug-2024	Outcome FILE	Board Meeting Outcome for Submission Of Quarterly Standalone And Financial Results For The Quarter Ended 30Th June 2024 Submission of Quarterly Standalone and Financial Results for the quarter ended 30th June 2024
BSE 08-Aug-2024	Outcome FILE	Submission Of Financial Results For The Quarter Ended 30Th June 2024 Submission of Standalone and Consolidated Results for the quarter ended 30th June 2024
BSE 01-Aug-2024	Intimation FILE	Board Meeting Intimation for Considering And Approval Of Unaudited Financial Results For The Period Ended 30Th June 2024 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve unaudited financial results for the period ended 30th June 2024
BSE 29-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Issue of Duplicate share certificate to Shesappa Suvarna
BSE 06-Jul-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Submission of Certificate under regulation 74(5) of SEBI (DP) Regulations.
BSE 28-Jun-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate by the shareholders
BSE 28-Jun-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of issue of duplicate share certificate to the shareholders detailed in the attached file

INSIDER TRADING FOR KILITCH DRUGS

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 23-Aug-2024 23-Aug-2024	Sell Inter-Se Transfer	841,046 @ 0.00 (5.23 %)	Bhavin Mukund Mehta
BSE 23-Aug-2024 23-Aug-2024	Buy Inter-Se Transfer	841,046 @ 0.00 (0.00 %)	Mira Bhavin Mehta
BSE 22-Apr-2022 22-Apr-2022	Buy Inter-Se Transfer	1,111,770 @ 0.00 (7.11 %)	Bhavin Mukund Mehta
BSE 22-Apr-2022 22-Apr-2022	Sell Inter-Se Transfer	1,111,770 @ 0.00 (7.13 %)	Mukund Mehta
BSE 11-Apr-2022 11-Apr-2022	Buy Others	1,111,770 @ 0.00 (7.14 %)	Mukund Mehta

BULK BLOCK DEALS FOR KILITCH DRUGS (INDIA) LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Bulk Block details found

DIVIDEND BY KILITCH DRUGS (INDIA) LIMITED

No dividend details found

SPLIT / BONUS BY KILITCH DRUGS (INDIA) LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Kilitch Drugs (India) Limited

Kilitch Drugs share price

CONSOLIDATED QUARTERLY RESULT FOR KILITCH DRUGS (INDIA) LIMITED

STANDALONE QUARTERLY RESULT FOR KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED ANNUAL RESULT FOR KILITCH DRUGS (INDIA) LIMITED

STANDALONE ANNUAL RESULT FOR KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED PROFIT / LOSS FOR KILITCH DRUGS (INDIA) LIMITED

STANDALONE PROFIT / LOSS FOR KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED CASH FLOW FOR KILITCH DRUGS (INDIA) LIMITED

STANDALONE CASH FLOW FOR KILITCH DRUGS (INDIA) LIMITED

CONSOLIDATED BALANCE SHEET FOR KILITCH DRUGS (INDIA) LIMITED

STANDALONE BALANCE SHEET FOR KILITCH DRUGS (INDIA) LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR KILITCH DRUGS (INDIA) LIMITED

FINANCIAL RATIOS (STANDALONE) FOR KILITCH DRUGS (INDIA) LIMITED

SHARE HOLDING PATTERN FOR KILITCH DRUGS (INDIA) LIMITED

PEER COMPARISON FOR KILITCH DRUGS (INDIA) LIMITED

CORPORATE ACTIONS FOR KILITCH DRUGS

CORPORATE ANNOUNCEMENTS FOR KILITCH DRUGS

INSIDER TRADING FOR KILITCH DRUGS

BULK BLOCK DEALS FOR KILITCH DRUGS (INDIA) LIMITED

DIVIDEND BY KILITCH DRUGS (INDIA) LIMITED

SPLIT / BONUS BY KILITCH DRUGS (INDIA) LIMITED